Limitations of randomized clinical trials in chronic diseases: Explanations and recommendations

Advances in Mind-Body Medicine

Volumn 18, Issue 2, 2002, Pages 14-21

  Pincus, Theodore ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DICLOFENAC; IBUPROFEN; METHOTREXATE; NAPROXEN; PENICILLAMINE; PIROXICAM; PLACEBO; PREDNISONE; PROPRANOLOL; SALAZOSULFAPYRIDINE;

CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LONG TERM CARE; META ANALYSIS; METHODOLOGY; OUTCOMES RESEARCH; PATIENT SELECTION; RANDOMIZATION; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; SOCIAL ASPECT; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TYPES OF STUDY;

CHRONIC DISEASE; CLINICAL PROTOCOLS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0036987643     PISSN: 07419783     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Sackett DL. The competing objectives of randomized trials. N Engl J Med. 1980;303(18):1059-1060.
2. Daniels M, Hill AB. Chemotherapy of pulmonary tuberculosis in young adults: An analysis of the combined results of three Medical Research Council trials. Br Med J. 1952;1:1162-1168.
3. Hill AB. Suspended judgment: Memories of the British streptomycin trial in tuberculosis. The first randomized clinical trial. Control Clin Trials. 1990;11(2):77-79.
4. Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum. 2001;44(7):1587-1598.
5. Felson DT. The verdict favors nonsteroidal anti-inflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments [editorial]. Arthritis Rheum. 2001;44(7):1477-1480.
6. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: Survey of 71 "negative" trials. N Engl J Med. 1978;299(13):690-694.
7. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979;301(26):1410-1412.
8. Huckisson EC. Important factors in the success and failure of clinical trials (closing remarks). Agents Actions Suppl. 1980;7:323-324.
9. Freireich EJ. The randomized clinical trial as an obstacle to clinical research. In: Varco RL, Delaney JP, eds. Controversy in Surgery. Philadelphia, Pa: W.B. Saunders, 1983.
10. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med. 1983;99(4):544-550.
11. Diamond GA, Forrester JS. Clinical trials and statistical verdicts: Probable grounds for appeal. Ann Intern Med. 1983;98(3):385-394.
12. Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med. 1983;309(22):1358-1361.
13. Bombardier C, Tugwell P. Controversies in the analysis of long-term clinical trials of slow acting drugs [editorial]. J Rheumatol. 1985;12(6):403-405.
14. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy - Randomized trials in individual patients. N Engl J Med. 1986;314(14):889-892.
15. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: Analysis of 122 studies. J Rheumatol. 1991;18(7):1008-1014.
16. Gotzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989;10(1):31-56.
17. Klippel JH. Winning the battle, losing the war? Another editorial about rheumatoid arthritis [editorial]. J Rheumatol. 1990;17(9):1118-1122.
18. Felson DT, Anderson JJ, Meenan RF. Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum. 1990;33:(1):140-149.
19. Sanz I, Dang H, Takei M, Talal N, Capra JD. VH sequence of a human anti-SM autoantibody. Evidence that autoantibodies can be unmutated copies of germline genes. J Immunol. 1989;142(3):883-887.
20. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995;345(8965):1616-1619.
21. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidence-based medicine" Am J Med. 1997;103(6):529-535.
22. Horwitz RI, Singer BH, Makuch RW, Viscoli CM. Clinical versus statistical considerations in the design and analysis of clinical research. J Clin Epidemiol. 1998;51(4):305-307.
23. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-1892.
24. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344(21):1594-1602.
25. Kaptchuk TJ. The double-blind randomized controlled trial: Gold standard or golden calf? J Clin Epidemiol. 2001;54(6):541-549.
26. Pincus T. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol. 1988;41(11):1037-1041.
27. Pincus T, Wolfe F. Gold therapy for rheumatoid arthritis: Challenges to traditional paradigms [response to letter]. Ann Intern Med. 1992;117:169-170.
28. Pincus T. Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum. 1993;23(2 Suppl 1):2-10.
29. Pincus T, Stein M. What is the best source of useful data on the treatment of rheumatoid arthritis: Clinical trials, clinical observations, or clinical protocols? J. Rheumatol. 1995;22(9):1611-1617.
30. Pincus T. Analyzing long-term outcomes of clinical care without randomized controlled clinical trials: The consecutive patient questionnaire database. Adv Mind Body Med. 1997;13(2):3-32.
31. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997;15(Suppl 17):S27-S38.
32. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of antitumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. In press.
33. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol. In press.
34. Chaput De Saintonge DM, Herxheimer A. Harnessing placebo effects in health care. Lancet. 1994;344(8928):995-998.
35. Spiro HM. Doctors, Patients, and Placebos. New Haven, Conn: Yale University Press; 1986.
36. Kaptchuk TJ. Powerful placebo: The dark side of the randomised controlled trial. Lancet. 1998;351(9117):1722-1725.
37. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-788.
38. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614-619.
39. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996;125(7):605-613.
40. Fuchs HA, Callahan LF, Kaye JJ, Brooks RH, Nance EP, Pincus T. Radiographic and joint count findings of the hand in rheumatoid arthritis: Related and unrelated findings. Arthritis Rheum. 1988;31(1):44-51.
41. Pincus T, Sokka T. Partial control of Core Data Set measures and Disease Activity Score (DAS) measures of inflammation does not prevent long-term damage: Evidence from longitudinal observations over 5-20 years. Clin Exp Rheumatol 2002;20(Suppl 27):S42-S48.
42. Ruberman W, Weinblatt E, Goldberg JD, Chaudhary BS. Psychosocial influences on mortality after myocardial infarction. N Engl J Med. 1984;311(9):552-559.
43. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: Results of two meta-analyses. Arthritis Rheum. 1990;33(10):1449-1461.
44. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol. 1992;19(12):1885-1894.
45. Weinblatt ME, Coblyn JS, Fraser PA, et al. Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum. 1987;30(1):11-17.
46. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis: Indications, contraindications, efficacy, and safety. Ann Intern Med. 1987;107:358-366.
47. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312(13):818-822.
48. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med. 1995;333(3):137-141.
49. Fletcher SW. Whither scientific deliberation in health policy recommendations? Alice in the Wonderland of breast cancer screening. N Engl J Med. 1997;36(16):1180-1183.
50. Ratain JS, Hochberg MC. Clinical trials: A guide to understanding methodology and interpreting results. Arthritis Rheum. 1990;33(1):131-139.